Effective May 1st, 2024, AbbVie will allow Arkansas hospital covered entities to order 340B products and/or place “Bill to/Ship to” replenishment orders at the 340B ceiling price for its contract pharmacies.

Contact: 
support@340besp.com

Effective May 1st, 2024, Astellas will include Venclexta products in its 340B contract pharmacy policy. 
Federal Grantees are not subject to limitations.

Contact: 
support@340besp.com

Effective April 17th, 2023, AbbVie will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations. *Updated policy now includes 90 drugs from original 25 added to exclusion list

Effective July 22nd, 2024, Alkermes will only provide 340B priced products to a single Contract Pharmacy of the Covered Entity does not have an in-house or wholly owned pharmacy. Covered entities located in Arkansas and Louisiana may use any contract pharmacies located in the respective states. Covered entities located in West Virginia are not subject to these restrictions.

Contact: 
support@340besp.com

Effective April 2nd, 2024, contract pharmacy arrangements between 340B covered entities located in Arkansas and contract pharmacies located in Arkansas are exempt from Amgen’s 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective March 19th, 2024, Federal Grantees are no longer exempt from Amgen’s 340B contract pharmacy policy. Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the covered entity doesn’t have an in-house pharmacy. If the covered entity does have an in-house pharmacy, they may designate a single contract pharmacy within 40 miles of the parent site with the provision of claims data.

Contact: 
support@340besp.com

Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

support@340Besp.com

Effective May 1st, 2024, Astellas will include Myrbetriq products in its 340B contract pharmacy policy and only provide 340B pricing for Xtandi® and Myrbetriq ^® products to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

Federal Grantees and covered entities in the state of Alabama* and Louisiana* are not subject to limitations.

*For contract pharmacies within the respective states

Contact: 
support@340besp.com

Effective October 17th, 2023, Astellas will provide 340B pricing for Xtandi^® to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas and an unlimited number of contract pharmacies located in Louisiana for covered entities in the state of Louisiana.

Contact:
support@340besp.com

Effective September 1st, 2023, Astellas will only provide 340B pricing for Xtandi® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.  

Contact: 
support@340BESP.com

Effective August 1st, 2023, AstraZeneca will transition the administration of their 340B contract pharmacy program to a third-party vendor.

Contact: 
support@340BESP.com 

*Calquence & Lynparza (October 1st, 2022) and Fasenra (January 1st, 2023) voluntary contracts restored.

Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single Contract Pharmacy.

Contact: membership@AstraZeneca.com 

Effective July 1st, 2024, Bausch & Lomb will only provide 340B pricing on its products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. 

Contact: 
support@340Besp.com

Effective March 12th, 2024, contract pharmacy arrangements between 340B covered entities located in Arkansas and contract pharmacies located in Arkansas are exempt from Bausch Health’s 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective June 26th, 2023, Bausch Health will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. 

Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. 

Contact:
support@340Besp.com

Effective June 24th, 2024, Bayer will include Nubeqa to its 340B Contract Pharmacy Policy.

Contact: 
support@340besp.com

Effective May 1st, 2024, Arkansas-based covered entities will be able to place Bill to/Ship to replenishment orders through contract pharmacies located within Arkansas.

Contact: 
support@340besp.com

Effective June 1st, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*Updated policy now includes Adempas

Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.

Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if the Covered Entity does not have an in-house pharmacy. Policy is limited to two drugs and doesn’t include Federal Grantees.

Effective June 6th, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in West Virginia for covered entities in the state of West Virginia.

Contact: 
support@340Besp.com

Effective May 27th, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in Louisiana for covered entities in the state of Louisiana.

Contact: 
support@340Besp.com

Effective May 1st, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas

Contact: 
support@340Besp.com

Effective August 1st, 2023, Boehringer Ingelheim will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. No central fill pharmacies.

Any covered entity that does not have an in-house pharmacy capable of dispensing specialty products may designate 1 specialty pharmacy from within BI’s limited distribution network for the purpose of dispensing OFEV.

Boehringer Ingelheim announced effective September 1st, 2022, an expansion to their contract pharmacy policy to include grantees enrolled in the Consolidated Health Center Program (CH/CHC). All other Federal Grantees not subject to limitations.

Contact:
support@340besp.com

Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1st, 2021, remain effective. Link to both notices below. 

Contact:
support@340Besp.com

support@340besp.com

Effective immediately, BMS will allow Arkansas covered entities to use any contract pharmacies located in Arkansas to dispense BMS 340B-eligible outpatient drugs.

Contact: 
BMS340B@bms.com

Contact: 
support@340besp.com

Effective March 28th, 2024, BMS will allow Arkansas covered entities to use any contract pharmacies properly licensed by the Arkansas State Board of Pharmacy to dispense all 340B-eligible covered outpatient drugs.

Contact: 
BMS340B@bms.com 

Effective November 1st, 2023, BMS will recognize up to three designated 340B contract pharmacy locations per 340B hospital that lacks an entity-owned pharmacy: one for IMiDs, a second for non-IMiDs, and a third for Camzyos.

*Camzyos effective July 1st, 2022 

At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.

Contact:
priceadmin@clovisoncology.com

Effective November 1, 2023, Eisai will only provide 340B priced products to a single contract pharmacy if the entity does not have an in-house pharmacy. 

Federal Grantees not subject to limitations.

*Additional contract pharmacy options may be available to Arkansas and Louisiana hospital covered entities

Contact: 
support@340besp.com  

Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.

Contact:
340B@lilly.com

Effective October 1st, 2023, EMD Serono’s updated contract pharmacy policy will include all EMD Serono marketed Products. EMD Serono will only provide 340B pricing products to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

*Serostim^®: covered entities may designate one additional contract pharmacy location in EMDS’s secure distribution network (the “SND”) for the purpose of dispensing Serostim only.   

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com  

Effective March 1, 2023, EMD Serono (EMDS) will only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.

Effective July 1st, 2024, Exelixis will allow a hospital covered entity to designate a single contract pharmacy within their specialty pharmacy network if the entity does not have an in-house pharmacy or wholly-owned (or common ownership) contract pharmacy. Claims data must be provided for contract pharmacy 340B dispensations. Federal Grantees not subject to limitations

Contact: 
340B@exelixis.com

Effective January 30th, 2024, Gilead will require covered entities to submit claims level data via 340BESP for their branded HCV products purchased at the 340B price for wholly-owned pharmacies.

Contact: 
support@340besp.com

Effective November 1st, 2023, GSK will allow Arkansas-based and Louisiana-based covered entities to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network. 

GSK will honor Arkansas- and Louisiana-based covered entities’ replenishment orders associated with a covered product dispensed within the respective states on or after August 1st, 2023.

Contact: 
support@340besp.com

support@340besp.com

Effective May 1, 2023, GSK will only provide 340B priced product to a single Contract Pharmacy if a covered entity doesn’t have an in-house pharmacy. An additional specialty pharmacy part of a limited pharmacy network may be designated.

*Updated policy now includes all GSK drugs

Contact:

support@340BESP.com

Effective July 1st, 2022, GSK will no longer offer voluntary 340B pricing on two orphan drugs (NUCALA and ZEJULA) to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact Covered Entities not subject to the orphan drug exclusion.

Contact:
US.340B@gsk.com 

Effective October 16th, 2023, Incyte will only provide 340B pricing on Opzelura^® to a single contract pharmacy located within 40 miles of the parent site if a hospital entity does not have an in-house pharmacy.

Federal Grantees are not subject to limitations.

Effective October 9th, 2023, Jazz will only provide 340B pricing for Epidiolex^® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com 

Effective April 1st, 2024, Liquidia will only provide 340B priced Yutrepia to a single Accredo or Caremark/CVS Specialty Contract Pharmacy, if the covered entity doesn’t have an in-house pharmacy, with the provision of claims data.
*Effective date subject to FDA’s final approval for Yutrepia

Contact: 
support@340besp.com

Effective June 6th, 2024, Merck will provide 340B pricing to an unlimited number of contract pharmacies for covered entities in the state of West Virginia. Winrevair will only be available through a limited specialty pharmacy network. 

Contact: 
340bdata@merck.com

Effective April 12th, 2024, Merck will include Winrevair in its 340B Contract Pharmacy Policy for hospitals or consolidated health center program covered entities and will be available through a limited specialty pharmacy network. The designated specialty pharmacy is in addition to the single contract pharmacy designation.

Federal Grantees (except CH grantee entities) are not subject to limitations.

Contact: 
340bdata@merck.com

Effective July 31st, 2023, Merck will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana and Arkansas if the hospital or CH covered entity registers and submits 340B claims data. Federal Grantees (except CH grantee entities) not subject to limitations.  

Contact: 
340bdata@merck.com

Effective June 12, 2023, Merck will only provide 340B priced product to a single contract pharmacy location, within 40 miles of the hospital Covered Entity or Consolidated Health Center, if they don’t have an in-house pharmacy. All other Federal Grantees are not subject to limitations. 

Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations. 

Contact:
340Bdata@merck.com

Effective May 1st, 2023, Novartis will only provide 340B priced product to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact:

Novartis.340B@novartis.com

Effective July 1st, 2024, Novo Nordisk will allow a maximum of two (2) contract pharmacy designations for all covered entities (e.g. two retail CPs, two specialty CPs, one retail and one specialty CP) regardless of if the covered entity has an in-house pharmacy. Federal Grantees may utilize an unlimited number of contract pharmacies through the provision of claims data via 340B ESP. 
There are no changes to wholly-owned pharmacies.

Contact: 
support@340besp.com

Effective February 1st, 2024, Novo Nordisk updated its contract pharmacy policy for Arkansas hospital covered entities only. They will allow two contract pharmacy designations for all Arkansas hospital covered entities without the provision of claims data. With the provision of claims data, an unlimited number of contract pharmacies are allowed if they are located within the state of Arkansas.
Federal Grantees not subject to limitations

Contact: 
support@340Besp.com
340BInfo@novonordisk.com  

Effective July 1st, 2023, Novo Nordisk will allow up to two contract pharmacy locations per 340B hospital (one retail, one specialty). Federal Grantees are not subject to limitations.

340BInfo@novonordisk.com

Effective June 6th, 2024, Organon will allow Kansas, Maryland and Mississippi-based covered entities to place “Bill to/Ship to” replenishment orders to unlimited contract pharmacies if claims level data is submitted via 340B ESP. Organon will allow West Virginia-based covered entities to place “Bill to/Ship to” replenishment orders to unlimited contract pharmacies without requiring claims submission.

Contact: 
support@340BESP.com

Effective July 1st, 2023, Organon will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity provides Claims Level Detail via 340B ESP platform. Federal Grantees not subject to limitations.

Effective November 1st, 2023, Pfizer will include additional products to the defined distribution model currently in place for Xeljanz. They will only provide the 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. 
Federal Grantees not subject to limitations.
*No modifications to Pfizer’s DON policy

Contact: 
340BCP@pfizer.com

Effective November 1st, 2023, Pfizer will change its process on acquiring Vyndamax^® and Vyndaquel^® at the 340B ceiling prices. A 340B covered entity may either apply to have its specialty pharmacy be a VYNDA Network Institution or establish a contract pharmacy relationship with a specialty contract pharmacy in the VYNDA Network.

Federal Grantees not subject to limitations.

Contact: 
340BCP@pfizer.com

Effective May 1st, 2023, Pfizer will only provide Xeljanz at a 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*No modifications to Pfizer’s DON policy

Contact:

340BCP@pfizer.com

Effective July 1st, 2024, Sanofi will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity doesn’t have an in-house pharmacy via the provision of claims data. Wholly owned pharmacies may only access 340B pricing if the covered entity lacks an in-house pharmacy, the wholly owned pharmacy is designated as the single contract pharmacy, and claims data is submitted. Claims data is not required for Consolidated Health Center (CH) entities. All other Federal Grantees, Children’s Hospitals, and Free Standing Cancer Hospitals are not subject to limitations. 

Contact: 
Sanofi340BOperations@Sanofi.com

Effective June 1, 2023, Sanofi will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity doesn’t have an in-house pharmacy. Federal Grantees, Children’s Hospitals, and Free Standing Cancer Hospitals are not subject to limitations. 

Contact: 
support@340besp.com

Effective December 1st, 2023, Sandoz will only provide 340B priced products to a single Contract Pharmacy located within 40 miles of the parent site, regardless of if a hospital covered entity has an in-house or wholly owned pharmacy, through provision of claims data via 340B ESP. Federal Grantees and covered entity hospitals located in Arkansas and Louisiana are not subject to limitations.

Contact:
support@340BESP.com 

Contact: 
support@340besp.com

Effective May 1st, 2024, Sumitomo will only provide 340B pricing for Aptiom, Gemtesa, and Myfembree to a single specialty Contract Pharmacy located within 40 miles of the parent site if the Covered Entity does not have an in-house pharmacy location. Sumitomo will only provide 340B pricing for Orgovyx to a single specialty Contract Pharmacy within SMPA’s ORGOVYX limited distribution network if the Covered Entity does not have an in-house pharmacy location capable of dispensing specialty products.
Louisiana and Arkansas covered entities are not subject to limitations.

Contact: 
support@340besp.com

Effective January 22nd, 2024, Takeda will only provide 340B pricing for select products to a single independent contract pharmacy or wholly owned contract pharmacy(ies) within 40 miles* of the parent site through provision of claims data via 340B ESP if a hospital covered entity doesn’t have an in-house pharmacy. If a hospital covered entity  does have an in-house pharmacy, it may also designate its wholly owned contract pharmacy(ies) through provision of claims data via 340B ESP.
Federal Grantees not subject to limitations
*Exception: Entyvio

Contact: support@340besp.com 

Effective February 16th, 2024, Takeda will include Inclusig, Alunbrig and Fruzaqla in its 340B Contract Pharmacy Policy. Only pharmacies in Takeda’s limited distribution network may be designated so the 40-mileage restriction does not apply.
Federal Grantees not subject to limitations

Contact: 
support@340besp.com

Contact: 
support@340besp.com

Effective April 8th, 2024, Teva will include Alvaiz in its contract pharmacy policy.

Contact: 
support@340besp.com

Effective September 26th, 2023, Teva will provide 340B priced products to an unlimited number of contract pharmacies for covered entities in the state of Arkansas.

Effective November 6th, 2023, Teva will include Austedo and Austedo XR product families to its contract pharmacy policy.

Contact:
support@340besp.com 

Effective July 5th, 2023, Teva will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the non-grantee entity does not have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact: 
support@340Besp.com

Effective August 1st, 2023, Teva will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana. Federal Grantees not subject to limitations. 

Contact: 
support@340Besp.com

Effective June 6th, 2024, UCB will provide 340B pricing for its products to an unlimited number of contract pharmacies located in West Virginia for covered entities in the state of West Virginia.

Contact: 
340B@ucb.com

Effective June 3rd, 2024, UCB will provide 340B pricing for its products to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas.

Contact: 
340B@ucb.com

Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.

Contact:
340B@ucb.com

Effective October 2nd, 2023, UCB updated its contract pharmacy policy to exclude wholly owned (and common ownership) pharmacy exemption. UCB will only provide 340B pricing to a single contract pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy.

Federal Grantees not subject to limitations.

Bimzelx was added to UCB’s contract pharmacy policy on October 19th, 2023.

Contact: 
340B@ucb.com

Effective July 2nd, 2024, Vertex will only provide 340B pricing on its Cystic Fibrosis products to a single Contract Pharmacy of the Covered Entity does not have an in-house pharmacy. Covered Entities located in Arkansas, Kansas, Louisiana, Maryland, Mississippi, or West Virginia, as well as Federal Grantees, are not subject to limitations.

Contact: 
support@340besp.com

Effective April 1, 2023, select Woodward Pharma products will only be available at a 340B ceiling price through direct distribution via DCS and no longer available via full line distributor 340B accounts.

*12 additional NDCs effective March 15th, 2023

Contact: 
340b-clientsservices@
directcustomersolutions.com